Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission

Clinical Cancer Research

Volumn 19, Issue 17, 2013, Pages 4770-4779

  Puchades Carrasco, Leonor ^a   Lecumberri, Ramón ^b   Martínez Ĺopez, Joaquín ^c   Lahuerta, Juan José ^c   Mateos, María Victoria ^d   Prośper, Felipe ^b   San Miguel, Jesús F ^d   Pineda Lucena, Antonio ^a  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETIC ACID; ARGININE; BORTEZOMIB; CARMUSTINE; CHOLESTEROL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GLUTAMINE; ISOLEUCINE; LIPID; LYSINE; MELPHALAN; PHENYLALANINE; PREDNISONE; THALIDOMIDE; TYROSINE; VINCRISTINE;

ACCURACY; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD SAMPLING; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; MALE; METABOLOMICS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

AGED; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; METABOLOMICS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM REGRESSION, SPONTANEOUS; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883482030     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2917     Document Type: Article

References (35)

1. Mamas M, Dunn WB, Neyses L, Goodacre R. The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol 2011;85:5-17.
2. Gebregiworgis T, Powers R. Application of NMR metabolomics to search for human disease biomarkers. Comb Chem High Throughput Screen 2012 Apr 5. [E-pub ahead of print]
3. Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem 2007;363:185-95. (Pubitemid 46428214)
4. KimK, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, et al. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteom 2009;8:558-70.
5. Ritchie SA, Heath D, Yamazaki Y, Grimmalt B, Kavianpour A, Krenitsky K, et al. Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age. BMC Gastroenterol 2010;10:140.
6. Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom 2010;24:613-20.
7. 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia 2010;24:788-97.
8. Guan W, Zhou M, Hampton CY, Benigno BB, Walker LD, Gray A, et al. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinform 2009;10:259.
9. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, et al. Detection of epithelial ovarian cancer using 1H-NMR- based metabonomics. Int J Cancer 2005;113:782-8. (Pubitemid 40101260)
10. 1H NMR-based metabolomics. Neoplasia 2009;11:269-76.
11. Tomita M, Kami K. Cancer. Systems biology, metabolomics, and cancer metabolism. Science 2012;336:990-1.
12. Bertini I, Cacciatore S, Jensen BV, Schou JV, Johansen JS, Kruhøffer M, et al. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res 2012;72:356-64.
13. Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010;11:934- 41.
14. Meiboom S, Gill D. Modifi ed spin-echo method for measuring nuclear relaxation times. Rev Sci Instrum 1958;29:688-701.
15. 13C NMR spectroscopy of human blood plasma. Anal Chem 1995;67:793-811.
16. Lindon JC, Tranter GE, Koppenaal D. Encyclopedia of spectroscopy and spectrometry. London: Academic Press; 2010.
17. Griffin JL, Atherton H, Shockcor J, Atzori L. Metabolomics as a tool for cardiac research. Nat Rev Cardiol 2011;8:630-43.
18. 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 2003;128:32-6.
19. Rajpal R, Dowling P, Meiller J, Clarke C, Murphy WG, O'Connor R, et al. A novel panel of protein biomarkers for predicting response to thalid-omide-based therapy in newly diagnosed multiple myeloma patients. Proteomics 2011;11:1391-402.
20. Terpos E, Politou M, Rahemtulla A. The role of markers of bone remodeling in multiple myeloma. Blood Rev 2005;19:125-42. (Pubitemid 40321139)
21. Bhattacharyya S, Epstein J, Suva LJ. Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools. Dis Markers 2006;22:245-55. (Pubitemid 44763277)
22. Body JJ. Metabolic sequelae of cancers (excluding bone marrow transplantation). Curr Opin Clin Nutr Metab Care 1999;2:339-44.
23. Baro L, Hermoso JC, Nunez MC, Jimenez-Rios JA, Gil A. Abnormalities in plasma and red blood cell fatty acid profiles of patients with colorectal cancer. Br J Cancer 1998;77:1978- 83.
24. Yavasoglu I, Tombuloglu M, Kadikoylu G, Donmez A, Cagirgan S, Bolaman Z. Cholesterol levels in patients with multiple myeloma. Ann Hematol 2008;87:223-8. (Pubitemid 351167225)
25. De la Luz-Hdez K. Metabolomics and mammalian cell culture. Croatia: Ute Roessner; 2012.
26. Sato JD, Cao HT, Kayada Y, Cabot MC, Sato GH, Okamoto T, et al. Effects of proximate cholesterol precursors and steroid hormones on mouse myeloma growth in serum-free medium. In Vitro Cell Dev Biol 1988;12:1223-8. (Pubitemid 19045975)
27. Whitford W. NS0 serum-free culture and applications. BioProcess Intl 2003;2003:36-47.
28. Robert RS, Hsu H. Amino acid metabolism of myeloma cells in culture. J Cell Sci 1976;21:609-15.
29. Wein J, Goetz IE. Asparaginase and glutaminase activities in culture media containing dialyzed fetal calf serum. In vitro 1973;9:186-93.
30. Grisolia FT, Cohen PP. Amino acid analysis of serum proteins in multiple myeloma. Cancer Res 1953;13:851-4.
31. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol 2007;5:68.
32. Chang H, Lee SY, Tang TC. Tumor lysis syndrome in patients with light chain multiple myeloma: report of two cases. Chang Gung Med J 2011;34:70-5.
33. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 2008;111:3131-6.
34. Kirito K. Therapeutic approaches for targeting hypoxia-inducible factor in multiple myeloma. Multiple myeloma - an overview. Croatia: InTech; 2012.
35. San-Miguel JF, Mateos MV. Can multiple myeloma become a curable disease? Haematologica 2011;96:1246-8.